Navigation Links
ESAs and a New Class of Late Stage Oral HIF-PH Inhibitors May Be Impacted by the Fact That Nephrologists Report Initiating ESAs at Lower Hemoglobins
Date:4/4/2013

t could also have implications for the late-stage oral HIF-PH inhibitors in development, for example Akebia Therapeutics' AKB-6548 or FibroGen's/Astellas's FG-4592/ASP1517."

The BioTrends' TreatmentTrends: Nephrology (US) Q4 2012 report, found that over 20 percent of nephrologists expect to use AKB-6548 and FG-4592/ASP1517 products after ESA failures, respectively. Late stage oral HIF-PH inhibitors manufacturers must be considering when and how these agents will be used, especially when physicians are waiting longer to initiate ESAs.ChartTrends®: Renal Anemia in CKD-ND 2012 (U.S.) is a syndicated report series, in which 226 U.S. nephrologists provide patient chart data on 1,130 CKD-ND patients in the U.S. to uncover the actual management related to renal anemia. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications, and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.

TreatmentTrends®: Nephrology (U.S.) is a syndicated quarterly report series, based on primary market research that provides a comprehensive view of the current and expected future management of renal anemia and bone and mineral metabolism in patients with kidney disease. The Q1 2013 wave published in March 2013 and the Q2 2013 wave will publish in June with survey comments due April 10, 2013.

About BioTrends Research GroupBioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharma
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
2. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
3. Medifast, Inc. Announces Favorable Resolution of Securities Class Action Lawsuit
4. Star Scientific Responds to Plaintiffs Purported Class Action Lawsuit
5. Class III Obese Patients Experience Adverse Events More Frequently Than the General Adverse Event Patient Population
6. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Affymax, Inc.
7. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
8. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
9. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
10. The law firms of Bernstein Litowitz Berger & Grossmann LLP and Labaton Sucharow LLP announce pendency of class action in In re Schering-Plough Corporation / ENHANCE Securities Litigation
11. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32
... SEATTLE, March 25 Cell Therapeutics, Inc.,(CTI) (Nasdaq: ... complete in,the phase III EXTEND (PIX301) clinical trial of ... non-Hodgkin,s lymphoma (NHL).,An analysis of the data is expected ... with the U.S. Food and Drug Administration (FDA) the ...
... Patients to ... Higher Rates of BARACLUDE Resistance -, PRINCETON, N.J., ... a continued low incidence of,resistance in nucleoside-naive patients through ... patients analyzed, no additional,patient developed resistance in the fifth ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 2Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 3Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 2BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 3BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 5BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 6
(Date:7/26/2014)... European security and surveillance radar market under defense aviation ... is expected to reach $1800 million by 2019 at ... that influence a country’s expenditure on radars. It provides ... The report also throws light on the leading competitors ... of the companies, it focuses on their financial position, ...
(Date:7/26/2014)... Recently, iFitDress.com, a popular supplier of ... unveiled its new range of high quality party outfits. ... brand new items; they are now provided at discounted ... is one of the leading suppliers in the international ... wholesale party dresses have flattering looks and ...
(Date:7/26/2014)... 26, 2014 As reported by ... changing based on 3 factors: smaller spaces, multi-generational access, ... bathroom trend of 2014 lists, including this article ... Amerec , a leading manufacturer of steam bath ... largely due to smaller spaces and an effort to ...
(Date:7/26/2014)... July 26, 2014 “Healthy teeth are important, ... those pearly whites shining,” says Community Health Center of Snohomish ... ." , They believe that an integration of medical and ... and well. Because of this, they encourage regular cleanings and ... dentist . , “Children and adults will find ...
(Date:7/26/2014)... OH (PRWEB) July 26, 2014 The U.S. ... guidelines list that includes a new medication guide for AndroGel ... a serious side-effect of taking the topical low testosterone medication, ... that AbbVie Inc., the makers of the low testosterone theapy ... symptoms of pain, swelling or redness as signs of a ...
Breaking Medicine News(10 mins):Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 4Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 5Health News:High Quality Wholesale Party Dresses Online at iFitDress.com 2Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5
... , ORANGE COUNTY, Calif., Oct. 14 Beckman Coulter, Inc. ... conference call on Thursday, October 29, 2009, at 5:00 p.m. ... Earnings will be released after the market closes. , (Logo: ... by dialing (877) 516-3365 or (706) 679-3246 and asking for ...
... American Academy of Physician Assistants (AAPA), representing 75,000 ... States, applauds the Senate Finance Committee,s vote to ... is committed to seeking health care reform legislation ... quality, affordable, cost-effective health care. , "Physician ...
... Payment Would Cover Just Two Percent of Lost Income ... Security Administration is expected to announce that seniors will receive ... checks next year. , President Obama,s call late this ... for seniors would make up just a tiny fraction of ...
... Inc. magazine ranked Texas Physical Therapy Specialists ... an exclusive ranking of the nation,s fastest-growing private companies. The ... segment of the economy--America,s independent-minded entrepreneurs. , "If you want ... look at the Inc. 500," said Inc. editor Jane Berentson. ...
... received artificial kidney treatment: study , WEDNESDAY, Oct. 14 (HealthDay ... older Americans in nursing homes who suffer kidney failure in ... published in the Oct. 15 issue of the New ... to lengthen or improve most patients, lives. , "The hope ...
... ... and CEO of Atlanta-based Jackson Healthcare, proposed a radical plan to ... stage as the current administration spearheads an aggressive reform of the ... propaganda that have saturated the news, Jackson’s core argument remains as ...
Cached Medicine News:Health News:American Academy of Physician Assistants Applauds Senate Finance Committee for Advancing Health Reform Legislation 2Health News:Social Security COLA: Tomorrow's Zero COLA Announcement for 2010 Could Cost Average Senior $10,134 2Health News:Inc. Magazine Unveils 28th Annual List of America's Fastest-Growing Private Companies - the Inc. 500 2Health News:Dialysis' Drawbacks Outweigh Benefits for Some Older Patients 2Health News:Dialysis' Drawbacks Outweigh Benefits for Some Older Patients 3Health News:Restoring the Physician/Patient Relationship: An Interview with Jackson Healthcare's CEO 2Health News:Restoring the Physician/Patient Relationship: An Interview with Jackson Healthcare's CEO 3Health News:Restoring the Physician/Patient Relationship: An Interview with Jackson Healthcare's CEO 4Health News:Restoring the Physician/Patient Relationship: An Interview with Jackson Healthcare's CEO 5
... VICTOR2 V ... fluorescence polarization, luminescence, ... and absorbance. A ... LANCE assay. All ...
This is the modular VICTOR2 multilabel counter with the TR-fluorometry, stacker and robot loading options.The addition of a xenon flash lamp brings the time-resolved fluorescence counting mode to th...
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
... readers available today operate with either one, ... speed) or use an imaging process to ... sensitivity and the individual signals can overlap). ... miniature lens array containing 96 parallel micro-objectives. ...
Medicine Products: